Guardant Health Partners with Patrick Dempsey to Boost Colorectal Cancer Screening Awareness
Event summary
- Guardant Health partners with actor and cancer advocate Patrick Dempsey to promote colorectal cancer screening using the Shield blood test.
- Shield, FDA-approved in 2024, offers a blood draw screening option for individuals 45 and over at average risk.
- Dempsey shares his experience with Shield to highlight its convenience and ease of use.
- Shield has shown a 93% completion rate in the first 100,000 tests ordered, significantly improving screening adherence.
The big picture
Guardant Health's partnership with Patrick Dempsey underscores the growing emphasis on early detection and convenient screening methods in the fight against colorectal cancer. With over 50,000 Americans expected to die from the disease annually, the need for innovative solutions like Shield is critical. This collaboration aims to address the significant screening gap, where more than 54 million Americans aged 45 and over avoid recommended screenings due to traditional methods' inconvenience.
What we're watching
- Market Adoption
- How Guardant Health will leverage Dempsey's influence to drive adoption of the Shield blood test among the eligible population.
- Regulatory Acceptance
- Whether the inclusion of Shield in national guidelines will further solidify its position as a primary screening option.
- Competitive Dynamics
- The pace at which Guardant Health can differentiate Shield from traditional and other emerging screening methods.
Related topics